WARREN, N.J. - Aquestive Therapeutics , Inc. (NASDAQ: NASDAQ:AQST), a pharmaceutical company, disclosed plans for an underwritten public offering of its common stock, according to a statement released on March 19, 2024.
The company will also provide underwriters a 30-day option to buy an additional 15% of the shares sold. While the offering is dependent on market conditions, there's no certainty regarding the completion or terms of the sale.
Joint bookrunning managers for the offering are Leerink Partners and Piper Sandler, with Oppenheimer & Co. serving as the lead manager. The company aims to allocate the net proceeds, alongside its existing capital, towards advancing its product pipeline, including treatments for severe allergic reactions and seizure clusters in young epilepsy patients.
The securities are being offered pursuant to a Registration Statement on Form S-3, effective since April 5, 2021. Details about the offering will be available in a preliminary prospectus supplement and an accompanying prospectus to be filed with the SEC, accessible on their website.
Aquestive focuses on developing oral alternatives to invasive therapies, with five products already commercialized by licensees globally. The company's proprietary pipeline targets central nervous system diseases and severe allergic reactions.
This announcement includes forward-looking statements, subject to risks and uncertainties that could affect the actual results of the offering, including market volatility and economic conditions. Investors are advised to consult the prospectus supplement and other SEC filings for risk factors and more detailed information.
The information for this article is based on a press release statement from Aquestive Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.